Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Seeks to Capitalize on the Growing Market for Psychedelics in Healthcare

  • The global psychedelics market is estimated to hit $10.75 billion in 2027, with the alternative antidepressant drug market being valued at $15.98 billion in 2023
  • Already, 65% of individuals dealing with PTSD, depression, and anxiety in the United States believe that psychedelic medicine should be made available
  • 83% of Americans living with these conditions are open to trying out alternative treatments
  • Delic seeks to capitalize on this growing demand for psychedelic alternatives, coupled with ongoing legislative and regulatory changes to grow its brand and increase value for its shareholders

While the psychedelics industry might be in its early stages, its potential is growing tremendously, particularly in the healthcare space. Already, it is estimated that by 2027, this market will be valued at about $10.75 billion. Furthermore, it is estimated that by 2023, the alternative antidepressant drug market, specifically, will be valued at $15.98 billion (https://ibn.fm/PPOym).

This growth will be attributed to the ongoing shift from traditional antidepressants to psychedelics, given their higher efficacy and significantly lower relapse rates after treatment. Additionally, the ongoing conversation about psychedelics and their usefulness, particularly for treating mental health diseases, has helped sensitize people about these products and driven up their adoption levels.

Delic Holdings (CSE: DELC) (OTCQB: DELCF), a leader in new medicines and treatments for a modern world, understands the potential that this industry has and, therefore, seeks to capitalize on it to not only benefit millions of people dealing with mental health issues but also create value for its shareholders.

Delic is banking on scientific research to prove the usefulness and effectiveness of psychedelics as an alternative treatment for specific mental conditions. It also relies on customer feedback to help push the conversation and further increase the sensitization of psychedelics for mental health treatment.

In a survey conducted by The Harris Poll on behalf of the company, it was noted that 65% of Americans who deal with Post-Traumatic Stress Disorder (“PTSD”), depression, and anxiety believe that psychedelic medicine ought to be made available to patients, especially those with treatment-resistant conditions. The study also revealed that 63% of Americans who have used prescription medications to treat these conditions acknowledged that while the medication helped, they still had to deal with residual feelings of their illnesses (https://ibn.fm/ZwFYM).

For context, back in 2020, over 7.3 million people were prescribed antidepressants in England alone, representing 17% of the adult population. However, it is estimated that only a third of individuals with depression benefitted then and benefit even today from these prescribed antidepressants, meaning over 4.8 million people found the drugs ineffective.

So far, at least 83% of Americans living with these specific conditions are open to trying out alternative treatments that are more effective than mainstream prescription medication and have fewer side effects. Psychedelics such as ketamine, MDMA, and psilocybin are worthy candidates.

“One of the key mooted advantages of psychedelics over existing drugs is that they work holistically to make the neuroplastic brain more malleable, therefore freeing people from long-held beliefs and memories- opening them evermore to new concepts and states of mind,” reported an article published in The Guardian.

“Thus, they allow the brain to reset and rewire itself, rather than simply dampening down symptoms and even causing serious side effects,” it added.

Already, policy toward psychedelics in the health care space is evolving. Legislative and regulatory changes are slowly coming into effect, allowing the psychedelics industry to grow and achieve its full potential. Delic seeks to capitalize on this to grow its brand and define its position in the global psychedelics space.

For more information, visit the company’s website at www.DelicCorp.com and the Meet Delic conference website at www.MeetDelic.com

NOTE TO INVESTORS: The latest news and updates relating to DELCF are available in the company’s newsroom at https://ibn.fm/DELCF

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.PsychedelicNewsWire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.

Archives

Select A Month

PsychedelicNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050